Neuroprotective effects of the stable nitroxide compound Tempol on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in the Nerve Growth Factor-differentiated model of pheochromocytoma PC12 cells

European Journal of Pharmacology

Volumn 549, Issue 1-3, 2006, Pages 50-57

  Lipman, Tatiana ^a   Tabakman, Rinat ^a   Lazarovici, Philip ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

MAPK (mitogen activated protein kinases); Neuroprotection; Neurotoxicity; Parkinson's disease; PC12 cells; Tempol

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CASPASE 3; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE GROWTH FACTOR; SCAVENGER; TEMPOL;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL DEATH; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; EXPOSURE; MITOCHONDRION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; STRESS; SURVIVAL;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL DIFFERENTIATION; CELL SURVIVAL; CYCLIC N-OXIDES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PC12 CELLS; PHOSPHORYLATION; RATS; SPIN LABELS;

EID: 33749154294     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.022     Document Type: Article

References (52)

1. Arai K., Lee S.R., Leyen K., Kurose H., and Lo E.H. Involvement of ERK MAP kinase in endoplasmic reticulum stress in SH-SY5Y human neuroblastoma cells. J. Neurochem. 89 (2004) 232-239
2. Bloch-Shilderman E., Jiang H., and Lazarovici P. Pardaxin, an ionophore neurotoxin, induces PC12 cell death: activation of stress kinases and production of reactive oxygen species. J. Nat. Toxins 11 (2002) 71-85
3. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 4546-4550
4. + neurotoxicity on NGF-differentiated PC12 cells. Cell Biol. Int. 19 (1995) 687-693
5. +. Brain Res. Mol. Brain Res. 119 (2003) 50-61
6. Cassarino D.S., Halvorsen E.M., Swerdlow R.H., Abramova N.N., Parker Jr. W.D., Sturgill T.W., and Bennett J.P. Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappa B in cellular models of Parkinson's disease. J. Neurochem. 74 (2000) 1384-1392
7. Dunigan C.D., and Shamoo A.E. Identification of the major transport pathway for the parkinsonism inducing neurotoxin 1-methyl-4-phenylpyridinium. Neuroscience 75 (1996) 37-41
8. (+) and MPTP in PC12 cells independent of reactive oxygen species formation. Brain Res. 905 (2001) 199-206
9. Fujita K., Lazarovici P., and Guroff G. Regulation of the differentiation of PC12 pheochromocytoma cells. Environ. Health Perspect. 80 (1989) 127-142
10. + increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res. 935 (2002) 32-39
11. Hahn S.M., Krishna M.C., DeLuca A.M., Coffin D., and Mitchell J.B. Evaluation of hydroxylamine tempol-H as an in vivo radioprotector. Free Radic Biol. Med. 28 (2000) 953-958
12. Hahn S.M., Tochner Z., Krishna C.M., Glass J., Wilson L., Samuni A., Sprague M., Venzon D., Glatstein E., Mitchell J.B., and Russo A. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res. 52 (1992) 1750-1753
13. Hartley A., Stone J.M., Heron C., Cooper J.M., and Schapira A.H. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J. Neurochem. 63 (1994) 1987-1990
14. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., and Hirsch E.C. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2875-2880
15. Jiang H., Zhang L., Koubi D., Kuo J., Groc L., Rodriguez A.I., Hunter T.J., Tang S., Lazarovici P., Gautam S.C., and Levine R.A. Roles of Ras-Erk in apoptosis of PC12 cells induced by trophic factor withdrawal or oxidative stress. J. Mol. Neurosci. 25 (2005) 133-140
16. Kimura S., Zhang G.X., Nagai Y., Miyata K., Nishiyama A., Shokoji T., Yao L., Fan Y.Y., Rahman M., Fujisawa Y., Miyatake A., and Abe Y. Time-dependent transition of tempol-sensitive reduction of blood pressure in angiotensin II-induced hypertension. J. Hypertens. 22 (2004) 2161-2168
17. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
18. -.or as SOD mimics?. J. Biol. Chem. 271 (1996) 26026-26031
19. Kulich S.M., and Chu C.T. Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and 6-hydroxydopamine cytotoxicity. J. Biosci. 28 (2003) 83-89
20. Langston J.W. MPT neurotoxicity: an overview and characterization of phases of toxicity. Life Sci. 36 (1985) 201-206
21. Leach M., Frank S., Olbrich A., Pfeilschifter J., and Thiemermann C. Decline in the expression of copper/zinc superoxide dismutase in the kidney of rats with endotoxic shock: effects of the superoxide anion radical scavenger, tempol, on organ injury. Br. J. Pharmacol. 125 (1998) 817-825
22. +-induced cell viability loss in differentiated PC12 cells. Neurochem. Res. 28 (2003) 1833-1841
23. + in PC12 pheochromocytoma cells: binding and biological studies. Neurosci. Lett. 94 (1988) 349-354
24. Matthews R.T., Klivenyi P., Mueller G., Yang L., Wermer M., Thomas C.E., and Beal M.F. Novel radical spin traps protect against malonate and MPTP neurotoxicity. Exp. Neurol. 157 (1999) 120-126
25. Mattson M.P., and Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med. 2 (2002) 215-231
26. McDonald M.C., Zacharowski K., Bowes J., Cuzzocrea S., and Thiemermann C. Tempol reduces infarct size in rodent models of regional myocardial ischemia and reperfusion. Free Radic. Biol. Med. 27 (1999) 493-503
27. Mielke K., and Herdegen T. JNK and p-38 stresskinases - degenerative effectors of signal-transduction-cascades in the nervous system. Brain Res. Mol. Brain Res. 75 (2000) 128-137
28. Moosmann B., and Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin. Investig. Drugs 11 (2002) 1407-1435
29. Nishiyama A., Yoshizumi M., Hitomi H., Kagami S., Kondo S., Miyatake A., Fukunaga M., Tamaki T., Kiyomoto H., Kohno M., Shokoji T., Kimura S., and Abe Y. The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J. Am. Soc. Nephrol. 15 (2004) 306-315
30. Park D.S., Morris E.J., Stefanis L., Troy C.M., Shelanski M.L., Geller H.M., and Greene L.A. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J. Neurosci. 18 (1998) 830-840
31. + by attenuation of mitochondrial membrane permeability change. Neurosci. Res. 46 (2003) 349-358
32. +-induced apoptosis. Eur. J. Neurosci. 17 (2003) 1563-1570
33. Rak R., Chao D.L., Pluta R.M., Mitchel J.B., Oldfield E.H., and Watson J.C. Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia. J. Neurosurg. 92 (2000) 646-651
34. Ribeiro L., Azevedo I., and Martel F. Comparison of the effect of cyclic AMP on the content and release of dopamine and 1-methyl-4-phenylpyridinium (Mpp+) in PC12 cells. Auton. Autacoid. Pharmacol. 22 (2002) 277-289
35. Rideout H.J., Larsen K.E., Sulzer D., and Stefanis L. Proteasomal inhibition leads to formation of ubiquitim/alpha-sinuclein immureactive inclusions in PC12 cells. J. Neurochem. 78 (2001) 899-908
36. Roth S., Shaikh A.R., Hennelly M.M., Li Q., Bindokas V., and Graham C.E. Mitogen-activated protein kinases and retinal ischemia. Invest.Ophthalmol. Vis. Sci. 44 (2003) 5383-5395
37. Salinas M., Martin D., Alvarez A., and Cudrado A. Akt1/PKBalpha protects PC12 cells against the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium and reduces the levels of oxygen-free radicals. Mol. Cell. Neurosci. 17 (2001) 67-77
38. Saporito M.S., Thomas B.A., and Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75 (2000) 1200-1208
39. Satoh T., Nakatsuka D., Watanabe Y., Nagata I., Kikuchi H., and Namura S. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci. Lett. 288 (2000) 163-166
40. Schapira A.H., and Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291 (2004) 358-364
41. Seaton T.A., Cooper J.M., and Schapira A.H. Free radical scavengers protect dopaminergic cell line from apoptosis induced by complex I inhibitors. Brain Res. 777 (1997) 110-118
42. Stocchi F., and Olanov W. Neuroprotection in Parkinson's disease: clinical trials. Ann. Neurol. Suppl. 53 (2003) S97-S99
43. Sheng G.Q., Zhang J.R., Pu X.P., Ma J., and Li C.L. Protective effect of verbascoside on 1-methyl-4-phenulperidinium ion-induced neurotoxicity in PC12 cells. Eur. J. Pharmacol. 451 (2002) 119-124
44. +-treated primary cortical neurons. Cell Biol. Int. 27 (2003) 768-777
45. Tabakman R., Lazarovici P., and Kohen R. Neuroprotective effects of carnosine and homocarnosine on pheochromocytoma PC12 cells exposed to ischemia. J. Neurosci. Res. 68 (2002) 463-469
46. Tabakman R., Jiang H., Schaefer E., Levine R.A., and Lazarovici P. Nerve growth factor pretreatment attenuates oxygen and glucose deprivation-induced c-Jun amino-terminal kinase 1 and stress-activated kinase p38α and p38β activation and confers neuroprotection in the pheochromocytoma PC12 model. J. Mol. Neurosci. 22 (2004) 237-249
47. Thiemermann C. Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammation. Crit. Care Med. Suppl. 31 (2003) S76-S84
48. Udassin R., Haskel Y., and Samuni A. Nitroxide radical attenuates ischaemia/reperfusion injury to the rat small intestine. Gut 42 (1998) 623-627
49. + -treated PC12 Cells: mechanisms of toxicity (MOT) analysis using bioinformatics tools. BMC Bioinformatics 6 (2005) 1-14
50. Yamada J., Yoshimura S., Yamakawa H., Sawada M., Nakagawa M., Hara S., Kaku Y., Iwama T., Naganawa T., Banno Y., Nakashima S., and Sakai N. Cell permeable ROS scavengers, Tiron and Tempol, rescue PC12 cell death caused by pyrogallol or hypoxia/reoxygenation. Neurosci. Res. 45 (2003) 1-8
51. Youdim M.B., and Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 4 (2004) 1130-1140
52. Weinberg A., Nylander K.D., Yan C., Ma L., Hsia C.J., Tyurin V.A., Kagan V.E., and Schor N.F. Prevention of catecholaminergic oxidative toxicity by 4-hydroxy-2,2,6,6-tetramethylpiperedine-N-oxyl and its recycling complex with polynitroxylated albumin, TEMPOL/PNA. Brain Res. 1012 (2004) 13-21